Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Eloxx Pharmaceuticals Inc (ELOX)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$12.74-1.39%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Oct 10, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for ELOX yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Manage capital allocation and equity financing activities | A supporting condition in Eloxx Pharmaceuticals Inc's published investment case. The stated target is Secure additional funding to support operations through 2026. | Intact | Failure to secure necessary funding by mid-2026 | Qualitative condition This condition has no defined numerical measure. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 10, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a speculative, development-stage business rather than an established earnings compounder. The long-term thesis is in a watch state, with low overall confidence, weak recent performance, and high risk.
The evidence does not provide a valuation measure or a clear account of market expectations, so whether ELOX is cheap or expensive versus peers cannot be assessed. No fragility gates fired, but that does not resolve the uncertainty around its losses and financing needs.
Near term, the company is likely to remain loss-making as it continues clinical and business development without revenue generation yet. Second-quarter 2026 operating and net losses increased, while efforts to manage expenses are behind; equity financing has also supported operations. A recent president transition is noted, but its effect is unclear.
Over the next one to three years, the thesis hinges on clinical and business progress, control of operating expenses, and access to financing. A weakening jobs trend could add pressure, while continued strength in Healthcare bellwethers could support the sector backdrop; misses or lower guidance from those companies could weaken that tailwind.
The multi-year view remains uncertain: ongoing development and a stronger sector backdrop are offset by rising losses, financing needs, and weak recent performance. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated in 2 quarters: 2025-Q2 and 2026-Q2 via material events filings. The company issued prefunded warrants and modified rights of security holders to raise capital. No direct financial impact figures are provided, but these actions indicate ongoing capital allocation efforts to support operations. The trajectory is consistent with maintaining liquidity through equity financing.
Advance clinical development and business updates | A primary condition in Eloxx Pharmaceuticals Inc's published investment case. The stated target is Continue advancing clinical programs through 2026. | Intact | Failure to progress in clinical trials by the end of 2026 | Qualitative condition This condition has no defined numerical measure. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextNewly stated in 2026-Q2 with a press release providing financial results and a business update. Financials show operating losses of $4.45M and net losses of $4.5M in 2026-Q2, consistent with ongoing development-stage operations. The trajectory reflects continued investment in clinical and business activities without revenue generation yet. Delivery assessment Oct 31, 2026 |
Manage operating expenses and cash flow | A supporting condition in Eloxx Pharmaceuticals Inc's published investment case. The stated target is Maintain operating losses below $4.5M per quarter. | Under Pressure | Operating losses exceed $4.5M in any quarter | Operating income: $-4.45M FY2026-Q2; GAAP. Published target: Maintain operating losses below $4.5M per quarter. Target period is not explicitly aligned with this observation. Aug 11, 2026-4,450,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated or implied in 6 quarters from 2023-Q3 through 2026-Q2. Operating income losses ranged from -$1.22M in 2025-Q1 to -$4.45M in 2026-Q2, with net losses similarly increasing to -$4.5M in 2026-Q2. The trajectory shows increasing operating losses consistent with ongoing development expenses, indicating limited progress in reducing operating losses. Delivery assessment Oct 31, 2026 |
Stored thesis · Oct 10, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-2.69 → $-2.19 · observed estimates
$0.17B → $0.17B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-09-07 | $-2.69 | $173,813,000 | 2 / 1 |
| 2026-09-08 | $-2.69 | $173,813,000 | 2 / 1 |
| 2026-09-09 | $-2.69 | $173,813,000 | 2 / 1 |
| 2026-09-10 | $-2.69 | $173,813,000 | 2 / 1 |
| 2026-09-11 | $-2.69 | $173,813,000 | 2 / 1 |
| 2026-09-12 | $-2.69 | $173,813,000 | 2 / 1 |
| 2026-09-13 | $-2.69 | $173,813,000 | 2 / 1 |
| 2026-09-14 | $-2.69 | $173,813,000 | 2 / 1 |
| 2026-09-15 | $-2.69 | $173,813,000 | 2 / 1 |
| 2026-09-16 | $-2.69 | $173,813,000 | 2 / 1 |
| 2026-09-17 | $-2.69 | $173,813,000 | 2 / 1 |
| 2026-09-18 | $-2.69 | $173,813,000 | 2 / 1 |
| 2026-09-19 | $-2.69 | $173,813,000 | 2 / 1 |
| 2026-09-20 | $-2.70 | $173,813,000 | 2 / 1 |
| 2026-09-21 | $-2.70 | $173,813,000 | 3 / 1 |
| 2026-09-22 | $-2.70 | $173,813,000 | 3 / 1 |
| 2026-09-23 | $-2.70 | $173,813,000 | 3 / 1 |
| 2026-09-24 | $-2.70 | $173,813,000 | 3 / 1 |
| 2026-09-25 | $-2.70 | $173,813,000 | 3 / 1 |
| 2026-09-26 | $-2.70 | $173,813,000 | 3 / 1 |
| 2026-09-27 | $-2.70 | $173,813,000 | 3 / 1 |
| 2026-09-28 | $-2.70 | $173,813,000 | 3 / 1 |
| 2026-09-29 | $-2.70 | $173,813,000 | 3 / 1 |
| 2026-09-30 | $-2.70 | $173,813,000 | 3 / 1 |
| 2026-10-01 | $-2.70 | $173,813,000 | 3 / 1 |
| 2026-10-02 | $-2.70 | $173,813,000 | 3 / 1 |
| 2026-10-03 | $-2.70 | $173,813,000 | 3 / 1 |
| 2026-10-04 | $-2.70 | $173,813,000 | 3 / 1 |
| 2026-10-05 | $-2.70 | $173,813,000 | 3 / 1 |
| 2026-10-06 | $-2.70 | $173,813,000 | 3 / 1 |
| 2026-10-07 | $-2.70 | $173,813,000 | 3 / 1 |
| 2026-10-08 | $-2.70 | $173,813,000 | 3 / 1 |
| 2026-10-09 | $-2.70 | $173,813,000 | 3 / 1 |
| 2026-10-10 | $-2.70 | $173,813,000 | 3 / 1 |
| 2026-10-11 | $-2.70 | $173,813,000 | 3 / 1 |
| 2026-10-12 | $-2.70 | $173,813,000 | 3 / 1 |
| 2026-10-13 | $-2.70 | $173,813,000 | 3 / 1 |
| 2026-10-14 | $-2.70 | $173,813,000 | 3 / 1 |
| 2026-10-15 | $-2.70 | $173,813,000 | 3 / 1 |
| 2026-10-16 | $-2.53 | $173,813,000 | 3 / 1 |
| 2026-10-17 | $-2.53 | $173,813,000 | 3 / 1 |
| 2026-10-18 | $-2.53 | $173,813,000 | 2 / 1 |
| 2026-10-19 | $-2.53 | $173,813,000 | 2 / 1 |
| 2026-10-20 | $-2.53 | $173,813,000 | 2 / 1 |
| 2026-10-21 | $-2.53 | $173,813,000 | 2 / 1 |
| 2026-10-22 | $-2.53 | $173,813,000 | 2 / 1 |
| 2026-10-23 | $-2.53 | $173,813,000 | 2 / 1 |
| 2026-10-24 | $-2.53 | $173,813,000 | 2 / 1 |
| 2026-10-25 | $-2.53 | $173,813,000 | 2 / 1 |
| 2026-10-26 | $-2.53 | $173,813,000 | 2 / 1 |
| 2026-10-27 | $-2.53 | $173,813,000 | 2 / 1 |
| 2026-10-28 | $-2.19 | $173,813,000 | 2 / 1 |
| 2026-10-29 | $-2.19 | $173,813,000 | 2 / 1 |
| 2026-10-30 | $-2.19 | $173,813,000 | 2 / 1 |
| 2026-10-31 | $-2.19 | $173,813,000 | 2 / 1 |
| 2026-11-01 | $-2.19 | $173,813,000 | 2 / 1 |
| 2026-11-02 | $-2.19 | $173,813,000 | 2 / 1 |
| 2026-11-03 | $-2.19 | $173,813,000 | 2 / 1 |
| 2026-11-04 | $-2.19 | $173,813,000 | 2 / 1 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 5 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 1 recorded
0 raises · 1 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.